N. I. Dedyulya
N. I. Dedyulya has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- A. A. Symanovich
Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
5 shared publications - I. A. Romanova
Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
5 shared publications - S. I. Krivenko
Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
5 shared publications - E. A. Nazarova
Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
4 shared publications - E. A. Primakova
Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
4 shared publications - E. G. Yurkina
Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
3 shared publications
Latest Publications
- Open Access
- 28 August 2025
- Published by Publishing House Belorusskaya Nauka in Doklady of the National Academy of Sciences of Belarus
- Vol. 69 (4) , 314–321
Comparative analysis of the profile of expression of molecular markers of mesenchymal stem cells obtained from placental-umbilical cord complex tissues, adipose tissue and bone marrow
Mesenchymal stem cells (MSCs) are multifunctional adult stem cells that can be derived from various tissues, such as adult adipose tissue, peripheral blood, bone marrow, neonatal placenta, and umbilical cord tissue. MSCs have the capacity for self-renewal and multidirectional differentiation. Despite the absence of differences in the expression of the main surface markers, MSCs obtained from tissues of the placenta-umbilical cord complex, adipose tissue and bone marrow differ significantly in their molecular profile. Cellular heterogeneity is ubiquitous across MSC cultures from different species and tissues. During the course of the study, the expression level of cell surface markers that characterize the heterogeneity of MSCs obtained from various sources was assessed. MSCs from all tissues express typical MSC markers on their surface, including CD13, CD73, CD105 and CD90, in the absence of expression of hematopoietic markers (CD14, CD34 and CD45), costimulatory molecules CD86, membrane protein CD154, adhesion molecules CD15, and markers of embryonic stem cells (TRA-1-81 and TRA-1-60R). However, they differed in the expression of stemness markers (October 4, Nanog), coinhibitory molecules (CD273, CD274, and CD200), cell adhesion molecules CD146, surface antigen SSEA-4, and transcription factor GATA4. The results on the molecular profile of MSCs as a heterogeneous cell population allow for the scientific substantiation of the choice of tissue source for the creation of biomedical cell products with specified therapeutic properties.
- 28 August 2025
- Published by Publishing House Belorusskaya Nauka in Doklady of the National Academy of Sciences of Belarus
- Vol. 69 (4) , 314–321
Open AccessComparative analysis of the profile of expression of molecular markers of mesenchymal stem cells obtained from placental-umbilical cord complex tissues, adipose tissue and bone marrow
Mesenchymal stem cells (MSCs) are multifunctional adult stem cells that can be derived from various tissues, such as adult adipose tissue, peripheral blood, bone marrow, neonatal placenta, and umbilical cord tissue. MSCs have the capacity for self-renewal and multidirectional differentiation. Despite the absence of differences in the expression of the main surface markers, MSCs obtained from tissues of the placenta-umbilical cord complex, adipose tissue and bone marrow differ significantly in their molecular profile. Cellular heterogeneity is ubiquitous across MSC cultures from different species and tissues. During the course of the study, the expression level of cell surface markers that characterize the heterogeneity of MSCs obtained from various sources was assessed. MSCs from all tissues express typical MSC markers on their surface, including CD13, CD73, CD105 and CD90, in the absence of expression of hematopoietic markers (CD14, CD34 and CD45), costimulatory molecules CD86, membrane protein CD154, adhesion molecules CD15, and markers of embryonic stem cells (TRA-1-81 and TRA-1-60R). However, they differed in the expression of stemness markers (October 4, Nanog), coinhibitory molecules (CD273, CD274, and CD200), cell adhesion molecules CD146, surface antigen SSEA-4, and transcription factor GATA4. The results on the molecular profile of MSCs as a heterogeneous cell population allow for the scientific substantiation of the choice of tissue source for the creation of biomedical cell products with specified therapeutic properties.
- Open Access
- 26 February 2025
- Published by Publishing House Belorusskaya Nauka in Doklady of the National Academy of Sciences of Belarus
- Vol. 69 (1) , 48-56
Functional characteristics of lymphocytes and plasma cytokine profile of allogeneic hematopoietic stem cell recipients as risk factors for the development of acute graft-versus-host disease
It has been shown that in order to identify patients with high risk for developing immunological complications after allogeneic hematopoietic stem cell transplantation (alloHSCT), it is advisable to measure quantitatively the proliferative activity of lymphocytes in alloHSCT recipients on the day of transplantation. A high donor and recipient lymphocyte stimulation index (>11.55) is an unfavorable factor in terms of development of a graft-versus-host disease (GVHD) in the early posttransplant period. In the course of the work, it was found that the study of the cytokine profile of blood plasma of alloHSC recipients in the early posttransplant period can be used as an additional method for diagnosing GVHD. The levels of IL-8 and IL-21 in the blood plasma of alloHSC recipients can act as potential biomarkers of acute GVHD.
- 26 February 2025
- Published by Publishing House Belorusskaya Nauka in Doklady of the National Academy of Sciences of Belarus
- Vol. 69 (1) , 48-56
Open AccessFunctional characteristics of lymphocytes and plasma cytokine profile of allogeneic hematopoietic stem cell recipients as risk factors for the development of acute graft-versus-host disease
It has been shown that in order to identify patients with high risk for developing immunological complications after allogeneic hematopoietic stem cell transplantation (alloHSCT), it is advisable to measure quantitatively the proliferative activity of lymphocytes in alloHSCT recipients on the day of transplantation. A high donor and recipient lymphocyte stimulation index (>11.55) is an unfavorable factor in terms of development of a graft-versus-host disease (GVHD) in the early posttransplant period. In the course of the work, it was found that the study of the cytokine profile of blood plasma of alloHSC recipients in the early posttransplant period can be used as an additional method for diagnosing GVHD. The levels of IL-8 and IL-21 in the blood plasma of alloHSC recipients can act as potential biomarkers of acute GVHD.
- Open Access
- 8 January 2025
- Published by Publishing House Belorusskaya Nauka in Doklady of the National Academy of Sciences of Belarus
- Vol. 68 (6) , 483-492
Usage of mesenchymal cells from the human placental-umbilical complex in the correction of liver failure in patients with decompensated liver cirrhosis
Acute-on-chronic liver failure is an acute liver decompensation in cirrhotic patients, which leads to organ failures and high short-term mortality. The treatment is based on the management of complications and, in severe cases, liver transplantation. Liver transplantation is the most effective treatment, but the lack of donor livers and a high cost of transplantation limit its broad application. Human placenta-umbilical cord complex derived mesenchymal stem cells (MSCs) can be considered as an allogeneic source for liver disease. The aim of the study was to assess the safety and potential effectiveness of systemic administration of mesenchymal cells from the human placental-umbilical cord complex for liver failure correction in patients with decompensated cirrhosis of the liver. An open interventional prospective case-control study was conducted, including 40 patients over 18 years of age with decompensated liver cirrhosis who were hospitalized awaiting liver transplantation. Laboratory efficacy of therapy was confirmed by a significant decrease in a total bilirubin level by 39 %, an increase in total protein was noted (by 11 %), as well as stabilization of coagulopathy (decrease in INR by 25 %). Systemic administration of mesenchymal cells of placental origin is a promising therapeutic option for patients with decompensated liver cirrhosis, allowing one to increase the waiting period for emergency liver transplantation and stabilize the clinical course of the disease.
- 8 January 2025
- Published by Publishing House Belorusskaya Nauka in Doklady of the National Academy of Sciences of Belarus
- Vol. 68 (6) , 483-492
Open AccessUsage of mesenchymal cells from the human placental-umbilical complex in the correction of liver failure in patients with decompensated liver cirrhosis
Acute-on-chronic liver failure is an acute liver decompensation in cirrhotic patients, which leads to organ failures and high short-term mortality. The treatment is based on the management of complications and, in severe cases, liver transplantation. Liver transplantation is the most effective treatment, but the lack of donor livers and a high cost of transplantation limit its broad application. Human placenta-umbilical cord complex derived mesenchymal stem cells (MSCs) can be considered as an allogeneic source for liver disease. The aim of the study was to assess the safety and potential effectiveness of systemic administration of mesenchymal cells from the human placental-umbilical cord complex for liver failure correction in patients with decompensated cirrhosis of the liver. An open interventional prospective case-control study was conducted, including 40 patients over 18 years of age with decompensated liver cirrhosis who were hospitalized awaiting liver transplantation. Laboratory efficacy of therapy was confirmed by a significant decrease in a total bilirubin level by 39 %, an increase in total protein was noted (by 11 %), as well as stabilization of coagulopathy (decrease in INR by 25 %). Systemic administration of mesenchymal cells of placental origin is a promising therapeutic option for patients with decompensated liver cirrhosis, allowing one to increase the waiting period for emergency liver transplantation and stabilize the clinical course of the disease.
- Open Access
- 31 January 2023
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 1,p. 71-82
The use of mesenchymal stem cells in the treatment of severe forms of new coronavirus infection COVID-19: a prospective observational study
INTRODUCTION: One of the promising treatments for COVID-19 aimed at correcting the immune response and reducing the level of pro-inflammatory cytokines is the use of mesenchymal stem cells (MSCs). There is evidence that MSCs, due to various mechanisms, are able to suppress the cytokine storm in patients with COVID-19. Thus, the use of MSCs can contribute to the suppression of inflammation and the regulation of immune homeostasis in patients with severe COVID-19. OBJECTIVE: Evaluation of the effect of mesenchymal stem cell (MSC) therapy on the course of severe forms of novel coronavirus infection, accompanied by “cytokine storm”. MATERIALS AND METHODS: A prospective single-center study included 39 patients treated for coronavirus infection on the basis of the intensive care unit and, after randomization, randomly divided into control (n = 16) and study groups (n = 23). An assessment of clinical, laboratory parameters in both groups and a cytokine profile in the study group was carried out. Outcomes were compared, the incidence of complications and clinical and laboratory parameters in both groups, and the cytokine profile in the study group. RESULTS: The use of MSCs in patients with severe forms of COVID-19 affected the outcomes of the disease, the duration of stay on mechanical ventilation, the course of acute respiratory distress syndrome (ARDS) (an increase in the oxygenation index in patients of the study group by 5, 7 days from administration in comparison with the control group). CONCLUSIONS: In patients treated with MSCs, there was a significant decrease in a number of pro-inflammatory cytokines.
- 31 January 2023
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 1,p. 71-82
Open AccessThe use of mesenchymal stem cells in the treatment of severe forms of new coronavirus infection COVID-19: a prospective observational study
INTRODUCTION: One of the promising treatments for COVID-19 aimed at correcting the immune response and reducing the level of pro-inflammatory cytokines is the use of mesenchymal stem cells (MSCs). There is evidence that MSCs, due to various mechanisms, are able to suppress the cytokine storm in patients with COVID-19. Thus, the use of MSCs can contribute to the suppression of inflammation and the regulation of immune homeostasis in patients with severe COVID-19. OBJECTIVE: Evaluation of the effect of mesenchymal stem cell (MSC) therapy on the course of severe forms of novel coronavirus infection, accompanied by “cytokine storm”. MATERIALS AND METHODS: A prospective single-center study included 39 patients treated for coronavirus infection on the basis of the intensive care unit and, after randomization, randomly divided into control (n = 16) and study groups (n = 23). An assessment of clinical, laboratory parameters in both groups and a cytokine profile in the study group was carried out. Outcomes were compared, the incidence of complications and clinical and laboratory parameters in both groups, and the cytokine profile in the study group. RESULTS: The use of MSCs in patients with severe forms of COVID-19 affected the outcomes of the disease, the duration of stay on mechanical ventilation, the course of acute respiratory distress syndrome (ARDS) (an increase in the oxygenation index in patients of the study group by 5, 7 days from administration in comparison with the control group). CONCLUSIONS: In patients treated with MSCs, there was a significant decrease in a number of pro-inflammatory cytokines.